Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Cencora, Inc. reported that one of its executive vice presidents, an officer of the company, sold shares of its common stock. On 12/19/2025, the officer disposed of 3,351 shares of Cencora common stock in an open market sale at a price of $342.1 per share. After this transaction, the officer directly beneficially owned 23,891.141 shares of Cencora common stock. This filing reflects a routine insider transaction reported on a Form 4 by a single reporting person.
Cencora, Inc. reported an insider stock transaction by President & CEO and director Robert P. Mauch. On 12/18/2025, he exercised a non-qualified stock option to acquire 3,763 shares of common stock at an exercise price of $86.09 per share, increasing his directly held common stock before the sale to 73,155 shares. On the same date, he reported a sale of 5,096 shares of common stock at a reported price of $343.45 per share. After these transactions, he directly beneficially owned 68,059 shares of Cencora common stock and 7,525 non-qualified stock options. The option exercised was originally scheduled to vest in four equal installments on 11/13/2020, 11/13/2021, 11/13/2022 and 11/13/2023.
Elizabeth Campbell filed a Rule 144 notice to sell 3,351 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 1146377.10, on or about 12/19/2025 on the NYSE. The issuer had 193993444 shares of this class outstanding.
The shares to be sold were acquired from the issuer as compensation via restricted stock vesting on three dates in November 2024: 1,257 shares on 11/08/2024, 1,391 shares on 11/09/2024, and 703 shares on 11/10/2024. Over the past three months, Campbell previously sold 1,886 common shares on 10/01/2025 for gross proceeds of 590846.08.
Cencora, Inc. disclosed that its President & CEO and Director, Robert P. Mauch, made a bona-fide gift of company stock. On 12/17/2025, he transferred 3,000 shares of common stock, coded as a gift, at a reported price of $0 per share, to a charitable donor advised fund. After this transaction, he beneficially owns 66,392 shares of Cencora common stock in direct ownership. The filing is made by a single reporting person and reflects a charitable transfer rather than a market sale or purchase.
Cencora, Inc. disclosed that one of its senior officers reported a stock sale. The reporting person, identified in the signature block as Lazarus Krikorian, who serves as SVP & Chief Accounting Officer, filed a Form 4 as an individual reporting person.
On 12/17/2025, the officer sold 4,031 shares of Cencora common stock at a price of $343.235 per share, coded as a disposition transaction. After this sale, the officer directly beneficially owned 17,154 shares of Cencora common stock. The filing shows the ownership as direct, with no derivative securities reported in the derivative securities table.
Cencora, Inc. reported an insider equity transaction by its Chief Financial Officer, James F. Cleary. On 12/17/2025, he exercised a non-qualified stock option for 45,154 shares of common stock at an exercise price of $86.09 per share. This option, originally vesting in four annual installments beginning in 2020, is now fully exercised with 0 options remaining from that grant.
To cover tax withholding related to the option exercise, 26,952 shares of common stock were disposed of, as noted by the transaction code "F" and the explanation of responses. After these transactions, Cleary directly held 153,143.3479 shares of Cencora common stock.
Cencora, Inc. director Dennis M. Nally reported a charitable stock gift. On 12/17/2025, he made a bona fide gift of 1,173 shares of Cencora common stock, recorded at a price of $0 per share, to a charitable donor advised fund.
After this transaction, Nally beneficially owns 12,304 shares of Cencora common stock in direct ownership. The filing reflects a personal charitable transfer rather than an open-market sale.
An insider of COR has filed a notice of intent to sell 1,677 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 12/19/2025. The shares have an aggregate market value of 578565.00, compared with 193,993,444 shares of the same class stated as outstanding. These shares were acquired on 11/10/2024 via restricted stock vesting from the issuer as compensation. The seller represents that they are not aware of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Shareholder Robert P. Mauch has filed a notice to sell 5,096 shares of the issuer’s common stock through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of December 18, 2025 and an aggregate market value of $1,750,221.20. The notice states that 193,993,444 shares of this class are outstanding. The shares to be sold were acquired from the issuer through restricted stock vesting in November 2024 (773 and 560 shares) and the exercise of stock options granted in November 2019 for 3,763 shares.
The filing also discloses that over the prior three months Mauch sold additional common shares in three transactions of 5,097, 5,097, and 5,096 shares, with gross proceeds ranging from $1,478,130.00 to $1,868,397.44.
Cencora, Inc. President & CEO and director Robert P. Mauch reported equity transactions dated 12/15/2025. He acquired 638 shares of common stock in a transaction coded “M” related to restricted stock units and then disposed of 638 shares in a transaction coded “F” at a price of $350.32 per share to cover FICA and associated income taxes on a 2025 restricted stock unit grant. The $350.32 price was the closing price of the company’s common stock on 12/15/2025 used to calculate this tax obligation. After these transactions, he beneficially owned 69,392 shares of common stock directly and 15,322 restricted stock units, including a 638-unit grant that vests in three equal installments on 11/12/2026, 11/12/2027 and 11/12/2028.